Expanding nilotinib access in clinical trials (ENACT) study in adult patients (Pts) with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in blast crisis (BC), accelerated phase (AP), or chronic phase (CP): Preliminary safety analysis

被引：1

作者：

Nicolini, Franck ^{[1
]}

Alimena, Giuliana ^{[2
]}

Al-Ali, Haifa-Kathrin ^{[3
]}

Zaritskey, Andrey ^{[4
]}

Shen, Zhixiang ^{[4
]}

Jootar, Saengsuree ^{[5
]}

Smith, Graeme ^{[6
]}

Hsu, Yanzhi ^{[7
]}

Veronese, Maria Luisa ^{[7
]}

Rizzieri, David A. ^{[4
]}

机构：

[1] Hop Edouard Herriot, Serv Hematol, Lyon, France

[2] Univ Roma La Sapienza, Rome, Italy

[3] Univ Leipzig, Med Klin & Poliklin 2, Leipzig, Germany

[4] St Petersburg Pavlov State Med Univ, Ctr Hematol, BMT Dept, St Petersburg, Russia

[5] Mahidol Univ, Salaya, Thailand

[6] Teaching Hosp, Leeds, W Yorkshire, England

[7] Novartis, E Hanover, NJ USA

来源：

关键词：

D O I：

10.1182/blood.V110.11.2960.2960

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2960

引用

页码：870A / 870A

页数：1